New approaches to diagnose and treat Alzheimer's disease : A glimpse of the future

Clinics in Geriatric Medicine

Volumn 17, Issue 2, 2001, Pages 393-410

  Galasko, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; EARLY DIAGNOSIS; ENZYME INHIBITION; ESTROGEN DEFICIENCY; GENE THERAPY; HUMAN; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; OXIDATIVE STRESS; PATIENT CARE; PRIMARY PREVENTION; REVIEW;

EID: 0035001457     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(05)70075-6     Document Type: Article

References (79)

1. Apoptosis
2. A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's Disease Cooperative Study
3. Inflammation and Alzheimer's disease
4. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration
5. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
6. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
7. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aß1-42/1-40 ratio in vitro and in vivo
8. Neuropathological staging of Alzheimer related changes
9. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia
10. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor
11. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
12. Predicting conversion to Alzheimer disease using standardized clinical information
13. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
14. Neuroinflammation and Alzheimer disease: Clinical and therapeutic implications
15. Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization
16. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: Power calculations and estimates of sample size to detect treatment effects
17. Phagocytosis and deposition of vascular β-amyloid in rat brains injected with Alzheimer β-amyloid
18. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
19. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein
20. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
21. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease
22. Amyloid, the presenilins, and Alzheimer's disease
23. Regional distribution of neuritic plaques in the non-demented elderly and subjects with very mild Alzheimer disease
24. Estrogen, cognition, and a woman's risk of Alzheimer's disease
25. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
26. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits
27. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model
28. Correlative memory deficits, A-beta elevation, and amyloid plaques in transgenic mice
29. 1-42 and tau levels in CSF
30. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease
31. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
32. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
33. Preclinical prediction of Alzheimer's disease using SPECT
34. The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation
35. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins
36. Ibuprofen suppresses plaque patholgy and inflammation in a mouse model for Alzheimer's disease
37. β-amyloid neurotoxicity requires fibril formation is inhibited by Congo Red
38. Tau in Alzheimer's disease
39. Oxidative alterations in Alzheimer's disease
40. Amyloid plaque core protein in Alzheimer's disease and Down's syndrome
41. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
42. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease
43. High-level neuronal expression of abeta 1-42 in wildtype human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
44. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment
45. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study
46. Presenilin 1 regulates pharmacologically distinct {gamma}-secretase activities: Implications for the role of PS in {gamma}-secretase cleavage
47. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline
48. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
49. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
50. Cohort study of vitamin C intake and cognitive impairment
51. Mild cognitive impairment: Clinical characterization and outcome
52. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state
53. Increased isoprostane biosynthesis in Alzheimer's disease: Correlation of a specific non invasive index of lipid peroxidation with disease severity
54. Mutant genes in familial Alzheimer's disease and transgenic models
55. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease
56. 1-42 dimmer derived from neuritic and vascular amyloid deposits of Alzheimer's disease
57. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
58. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease
59. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
60. β-peptide immunization: A possible new treatment for Alzheimer's disease
61. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
62. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease: A proton MR spectroscopic imaging and MRI study
63. Translating cell biology into therapeutic advances in Alzheimer's disease
64. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
65. Production of the Alzheimer amyloid β protein by normal proteolytic processing
66. Cellular mechanisms of beta-amyloid prduction and secretion
67. HRT and dementia
68. Protein kinase C-dependent alpha-secretase competes with beta-secretase cleavage of amyloid-beta precursor protein in the trans-Golgi network
69. Molecular genetics of Alzheimer's disease
70. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization
71. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
72. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme
73. Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly
74. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study
75. Human apolipoprotein E: The Alzheimer's disease connection
76. Caspases and neurodegeneration: On the cutting edge of new therapeutic approaches
77. Clinical trial designs for demonstrating disease-course-altering effects in dementia
78. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease
79. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing